trending Market Intelligence /marketintelligence/en/news-insights/trending/nvkue0d2fidpg0fkdmjp2w2 content esgSubNav
In This List

CStone Pharmaceuticals completes $260M financing

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


CStone Pharmaceuticals completes $260M financing

China's CStone Pharmaceuticals Co. Ltd. completed a $260 million series B financing.

The funding was led by Singapore sovereign wealth fund GIC Pvt. Ltd. with participation from new investors including Sequoia China, Yunfeng Capital and 6 Dimensions Capital among others.

CStone previously raised $150 million in its series A financing in 2016.

The Chinese biopharmaceutical company plans to use the proceeds to develop its anti-PD-L1 experimental drug, CS1001, and for the expansion of its pipeline.

CS1001 is part of a class of immune system-boosting drugs called checkpoint inhibitors. Inhibitor drugs target immune checkpoints such as PD-L1 and CTLA-4 to prevent cancer cells from downregulating and hiding from the body's immune system.